Your browser doesn't support javascript.
loading
[Are SARS-CoV-2 reactive T cells detectable and potentially protective in patients under anti-CD20 treatment with an impaired humoral response?] / Sind SARS-CoV-2-reaktive T­Zellen bei Patienten unter Anti-CD20-Therapie mit einer beeinträchtigten humoralen Antwort nachweisbar und potenziell protektiv?
Braun, J; Westhoff, T; Baraliakos, X; Babel, N.
Affiliation
  • Braun J; Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland. juergen.braun@elisabethgruppe.de.
  • Westhoff T; Medizinische Klinik I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Deutschland.
  • Baraliakos X; Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland.
  • Babel N; Center for Translational Medicine and Immune Diagnostics Laboratory, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Deutschland.
Z Rheumatol ; 80(9): 879-883, 2021 Nov.
Article in De | MEDLINE | ID: mdl-34529110
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: De Journal: Z Rheumatol Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: De Journal: Z Rheumatol Year: 2021 Type: Article